Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship.

Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C, Mera A, Sivanadiyan K, Harries M, Sullivan R, Pinder SE, Garmo H, Holmberg L.

Eur J Cancer. 2014 Jul;50(10):1697-705. doi: 10.1016/j.ejca.2014.04.002.

PMID:
24768572
2.

Factors affecting survival in breast cancer patients following bone metastasis.

Yavas O, Hayran M, Ozisik Y.

Tumori. 2007 Nov-Dec;93(6):580-6.

3.

Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.

Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H.

Cancer. 2006 Jan 1;106(1):35-41.

4.

Predictors of early distant metastasis in women with breast cancer.

Rosa Mendoza ES, Moreno E, Caguioa PB.

J Cancer Res Clin Oncol. 2013 Apr;139(4):645-52. doi: 10.1007/s00432-012-1367-z.

PMID:
23283528
5.

The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.

Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J.

BMC Cancer. 2010 Dec 3;10:664. doi: 10.1186/1471-2407-10-664.

6.

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.

Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM.

Breast Cancer Res Treat. 2009 Nov;118(1):131-7. doi: 10.1007/s10549-008-0295-8.

PMID:
19189211
7.

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.

St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F.

Hum Pathol. 2012 Mar;43(3):398-404. doi: 10.1016/j.humpath.2011.05.009.

PMID:
21840040
8.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
9.

Primary and secondary distant metastatic breast cancer: two sides of the same coin.

Güth U, Magaton I, Huang DJ, Fisher R, Schötzau A, Vetter M.

Breast. 2014 Feb;23(1):26-32. doi: 10.1016/j.breast.2013.10.007.

PMID:
24215983
10.

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.

Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M.

J Clin Oncol. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440.

PMID:
23589556
12.

The consequence of undertreating breast cancer in the elderly.

Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL.

J Am Coll Surg. 2001 Jun;192(6):698-707.

PMID:
11400963
13.
14.

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.

Arpino G, Bardou VJ, Clark GM, Elledge RM.

Breast Cancer Res. 2004;6(3):R149-56.

15.

[Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].

Bensouda Y, André F, Boulet T, Al-Ghuzlan A, Conforti R, Troalen F, Bourgier C, Errihani H, Spielmann M, Delaloge S.

Bull Cancer. 2009 Oct;96(10):923-8. doi: 10.1684/bdc.2009.0919. French.

16.

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

Hum Pathol. 2008 Dec;39(12):1809-15. doi: 10.1016/j.humpath.2008.05.010.

PMID:
18715613
17.

Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.

Karray-Chouayekh S, Trifa F, Khabir A, Sellami-Boudawara T, Frikha M, Gargouri A, Mokdad-Gargouri R.

Histol Histopathol. 2012 Mar;27(3):377-85.

PMID:
22237715
18.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
19.

Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?

Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D.

Breast Cancer Res Treat. 2010 Jul;122(1):27-34. doi: 10.1007/s10549-010-0917-9. Review.

PMID:
20454925
20.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

Items per page

Supplemental Content

Support Center